🔗 Share this article

While the United States continues making sweeping changes to its vaccination recommendations, a particular individual appears in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning Covid vaccinations throughout the global health crisis and has zeroed in on possible fatalities after COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Schedule

Agency leaders were set to reveal major revisions to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s immunization schedule, it is understood – a major change that would put the US at odds with many the international standard with no evidence for improved outcomes. This reveal has been pushed back until the coming year.

Rather than the director of the vaccine center, Høeg is scheduled to present at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this calendar year.

A Shift at the FDA

The acting appointment may indicate a tighter collaboration between the drug and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric shot schedules in the US to become more like the Danish model, a society with universal health coverage and a population approximately the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccination policy – typically the purview of Dr. Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Doubts Over Background

The appointee has little discernible experience in drug development, regulation or management, which has been typical for past directors of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a large organization. She lacks background in drug approvals.”

Previous directors of CBER would “grasp legal statutes and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Frankly, she doesn’t have the kind of background that former directors who ran the center have had.”

The drug center has an vast range of responsibilities at the FDA, she pointed out.

“Everybody just pays attention on the innovative therapies, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and more, and every single one must be managed,” Dr. Woodcock said. “The thing you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial management component to the position, which manages over 5,000 personnel. “It’s a enormous leadership role, if you execute it properly,” she added.

Agency Reaction and Contentious Policies

In response to inquiries about Høeg’s qualifications and whether this appointment signifies increased cooperation among regulatory chiefs on immunizations, a press secretary stated that the “inquiries are based on incorrect presumptions”.

“Her resume aligns with the responsibilities of her job,” the representative stated, citing the time Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial fast-track approval initiative, a contentious one-day drug-approval program that allegedly worried her former heads. “By what process are these therapies being selected for this expedited pathway? Who is making the decisions?” Dr. Howard questioned. “There is a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the agency looks to be trending towards less stringent oversight of pharmaceuticals, except for shots.”

Established Track Record on Immunizations

Concerning vaccines, Høeg has a more established, if troubling, history, Howard said. She released a study using unconfirmed crowd-sourced reports to determine the incidence of myocarditis following COVID-19 vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are riskier than they are.

Included in her “desired changes” for the new government encompassed revising regulations for new vaccines and ending “unnecessary” vaccines, she stated following the vote on a podcast. At the agency, Dr. Høeg has reportedly proposed excluding teenage boys from getting Covid vaccines.

“She is an thorough ideologue who commences with her beliefs and reverse-engineers to retrofit the data in a highly deceptive, fraudulent way,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow dissenters, {like|